We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Karyopharm Therapeutics Inc (KPTI) USD0.0001

Sell:$0.79 Buy:$0.79 Change: $0.0201 (2.48%)
NASDAQ:1.30%
Market closed |  Prices as at close on 4 December 2024 | Switch to live prices |
Sell:$0.79
Buy:$0.79
Change: $0.0201 (2.48%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 4 December 2024 | Switch to live prices |
Sell:$0.79
Buy:$0.79
Change: $0.0201 (2.48%)
Market closed |  Prices as at close on 4 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.

Contact details

Address:
85 Wells Avenue, Second Floor
NEWTON
02459
United States
Telephone:
+1 (617) 6580600
Website:
https://karyopharm.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
KPTI
ISIN:
US48576U1060
Market cap:
$101.50 million
Shares in issue:
125.31 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Richard Paulson
    President, Chief Executive Officer, Director
  • Sohanya Cheng
    Executive Vice President, Chief Commercial Officer
  • Stuart Poulton
    Executive Vice President, Chief Development Officer
  • Reshma Rangwala
    Executive Vice President, Chief Medical Officer
  • Michael Mano
    Senior Vice President, General Counsel, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.